{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-024042","form_type":"8-K","ticker":"ZLAB","cik":"0001704292","company_name":"Zai Lab Ltd","filed_at":"2023-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.121951+00:00","generated_at":"2026-06-13T14:09:55.138719+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"China NMPA approves Zai Lab's VYVGART for generalized myasthenia gravis","bullets":["NMPA approved VYVGART (efgartigimod alfa) as add-on for anti-AChR+ gMG adults.","Phase 3 ADAPT: 68% responders on MG-ADL vs 30% placebo (p<0.0001) in first cycle.","Zai Lab to seek National Reimbursement Drug List inclusion for broader patient access.","Zai Lab holds exclusive license from argenx to develop/commercialize in mainland China, HK, Macau, Taiwan.","VYVGART is the first approved FcRn antagonist for gMG in China; ~200,000 MG patients in country."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-024042","json":"https://secwatch.observer/filing/0001628280-23-024042.json","markdown":"https://secwatch.observer/filing/0001628280-23-024042.md","text":"https://secwatch.observer/filing/0001628280-23-024042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704292/000162828023024042/0001628280-23-024042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704292/000162828023024042/zlab-20230630.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T14:09:55.138719+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}